<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37523555</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>02</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>120</Volume><Issue>32</Issue><PubDate><Year>2023</Year><Month>Aug</Month><Day>08</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Elevated &#x3b1;5 integrin expression on myeloid cells in motor areas in amyotrophic lateral sclerosis is a therapeutic target.</ArticleTitle><Pagination><StartPage>e2306731120</StartPage><MedlinePgn>e2306731120</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e2306731120</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.2306731120</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a fatal disease affecting upper and lower motor neurons. Microglia directly interact with motor neurons and participate in the progression of ALS. Single-cell mass cytometry (CyTOF) analysis revealed prominent expression of &#x3b1;5 integrin in microglia and macrophages in a superoxide dismutase-1 G93A mouse model of ALS (SOD1<sup>G93A</sup>). In postmortem tissues from ALS patients with various clinical ALS phenotypes and disease duration, &#x3b1;5 integrin is prominent in motor pathways of the central and peripheral nervous system and in perivascular zones associated with the blood-brain barrier. In SOD1<sup>G93A</sup> mice, administration of a monoclonal antibody against &#x3b1;5 integrin increased survival compared to an isotype control and improved motor function on behavioral testing. Together, these findings in mice and in humans suggest that &#x3b1;5 integrin is a potential therapeutic target in ALS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chiot</LastName><ForeName>Aude</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Molecular Microbiology and Immunology, Oregon Health and Science University, Portland, OR 97239.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Behavioral and Systems Neuroscience, Oregon Health and Science University, Portland, OR 97239.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roemer</LastName><ForeName>Shanu F</ForeName><Initials>SF</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryner</LastName><ForeName>Lisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Pasithea Therapeutics, Molecular Research Laboratories, South San Francisco, CA 94080.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bogachuk</LastName><ForeName>Alina</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Molecular Microbiology and Immunology, Oregon Health and Science University, Portland, OR 97239.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Behavioral and Systems Neuroscience, Oregon Health and Science University, Portland, OR 97239.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Emberley</LastName><ForeName>Katie</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0003-2333-2289</Identifier><AffiliationInfo><Affiliation>Department of Molecular Microbiology and Immunology, Oregon Health and Science University, Portland, OR 97239.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Behavioral and Systems Neuroscience, Oregon Health and Science University, Portland, OR 97239.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Jungers Center for Neurosciences Research, Department of Neurology, Oregon Health and Science University, Portland, OR 97239.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brownell</LastName><ForeName>Dillon</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Molecular Microbiology and Immunology, Oregon Health and Science University, Portland, OR 97239.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Behavioral and Systems Neuroscience, Oregon Health and Science University, Portland, OR 97239.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jimenez</LastName><ForeName>Gisselle A</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>Department of Molecular Microbiology and Immunology, Oregon Health and Science University, Portland, OR 97239.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Behavioral and Systems Neuroscience, Oregon Health and Science University, Portland, OR 97239.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leviten</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Pasithea Therapeutics, Molecular Research Laboratories, South San Francisco, CA 94080.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Woltjer</LastName><ForeName>Randall</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Pathology, Oregon Health and Science University, Portland, OR 97239.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dickson</LastName><ForeName>Dennis W</ForeName><Initials>DW</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steinman</LastName><ForeName>Lawrence</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-2437-2250</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA 94305.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ajami</LastName><ForeName>Bahareh</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0003-0320-4677</Identifier><AffiliationInfo><Affiliation>Department of Molecular Microbiology and Immunology, Oregon Health and Science University, Portland, OR 97239.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Behavioral and Systems Neuroscience, Oregon Health and Science University, Portland, OR 97239.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG062677</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 NS084974</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG063911</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>07</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D039482">Integrin alpha5</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039482" MajorTopicYN="N">Integrin alpha5</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009044" MajorTopicYN="Y">Motor Cortex</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008264" MajorTopicYN="N">Macrophages</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">macrophages</Keyword><Keyword MajorTopicYN="N">microglial cells</Keyword><Keyword MajorTopicYN="N">&#x3b1;5 integrintherapeutic</Keyword></KeywordList><CoiStatement>L.R. and M.L. are employees at Pasithea. L.S. is a Board Member at Pasithea. L.R., M.L., and L.S. have stock ownership greater than $5,000. L.R. has a patent application on anti-&#x3b1;5 integrin for ALS. L.S. and B.A. have a patent application for anti-&#x3b1;5 integrin for ALS and MS, assigned to Stanford University. J.K. and B.A. were among 96 coauthors on a paper in Neuron in 2022, &#x201c;Microglia states and nomenclature: A field at its crossroads.&#x201d;</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>2</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>31</Day><Hour>19</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>31</Day><Hour>15</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37523555</ArticleId><ArticleId IdType="pmc">PMC10410747</ArticleId><ArticleId IdType="doi">10.1073/pnas.2306731120</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Soares P., et al. , Drug discovery and amyotrophic lateral sclerosis: Emerging challenges and therapeutic opportunities. Ageing Res. Rev. 83, 101790 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36402404</ArticleId></ArticleIdList></Reference><Reference><Citation>Clement A. M., et al. , Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science 302, 113&#x2013;117 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">14526083</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers D. R., et al. , Wild-type microglia extend survival in PU.1 knockout mice with familial amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. U.S.A. 103, 16021&#x2013;16026 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1613228</ArticleId><ArticleId IdType="pubmed">17043238</ArticleId></ArticleIdList></Reference><Reference><Citation>Boill&#xe9;e S., et al. , Onset and progression in inherited ALS determined by motor neurons and microglia. Science 312, 1389&#x2013;1392 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16741123</ArticleId></ArticleIdList></Reference><Reference><Citation>Lobsiger C. S., et al. , Schwann cells expressing dismutase active mutant SOD1 unexpectedly slow disease progression in ALS mice. Proc. Natl. Acad. Sci. U.S.A. 106, 4465&#x2013;4470 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2657393</ArticleId><ArticleId IdType="pubmed">19251638</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamanaka K., et al. , Astrocytes as determinants of disease progression in inherited ALS. Nat. Neurosci. 11, 251&#x2013;253 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3137510</ArticleId><ArticleId IdType="pubmed">18246065</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang S. H., et al. , Degeneration and impaired regeneration of gray matter oligodendrocytes in amyotrophic lateral sclerosis. Nat. Neurosci. 16, 571&#x2013;579 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3637847</ArticleId><ArticleId IdType="pubmed">23542689</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiot A., et al. , Modifying macrophages at the periphery has the capacity to change microglial reactivity and to extend ALS survival. Nat. Neurosci. 23, 1339&#x2013;1351 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33077946</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexianu M. E., Kozovska M., Appel S. H., Immune reactivity in a mouse model of familial ALS correlates with disease progression. Neurology 57, 1282&#x2013;1289 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11591849</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall E. D., Oostveen J. A., Gurney M. E., Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS. Glia 23, 249&#x2013;256 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9633809</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu I. M., et al. , A neurodegeneration-specific gene-expression signature of acutely isolated microglia from an amyotrophic lateral sclerosis mouse model. Cell Rep. 4, 385&#x2013;401 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4272581</ArticleId><ArticleId IdType="pubmed">23850290</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J., et al. , Microglial activation and TDP-43 pathology correlate with executive dysfunction in amyotrophic lateral sclerosis. Acta Neuropathol. 27, 417&#x2013;428 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3595560</ArticleId><ArticleId IdType="pubmed">22210083</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J., et al. , Microglial activation correlates with disease progression and upper motor neuron clinical symptoms in amyotrophic lateral sclerosis. PLoS One 7, 13&#x2013;15 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3375234</ArticleId><ArticleId IdType="pubmed">22720079</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiot A., Lobsiger C. S., Boill&#xe9;e S., New insights on the disease contribution of neuroinflammation in amyotrophic lateral sclerosis. Curr. Opin. Neurol. 32, 764&#x2013;770 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31306211</ArticleId></ArticleIdList></Reference><Reference><Citation>Atanasio A., et al. , C9orf72 ablation causes immune dysregulation characterized by leukocyte expansion, autoantibody production, and glomerulonephropathy in mice. Sci. Rep. 6, 23204 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4793236</ArticleId><ArticleId IdType="pubmed">26979938</ArticleId></ArticleIdList></Reference><Reference><Citation>Burberry A., et al. , Loss-of-function mutations in the C9ORF72 mouse ortholog cause fatal autoimmune disease. Sci. Transl. Med. 8 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5024536</ArticleId><ArticleId IdType="pubmed">27412785</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Rourke J. G., et al. , C9orf72 is required for proper macrophage and microglial function in mice. Science 1979, 1324&#x2013;1329 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5120541</ArticleId><ArticleId IdType="pubmed">26989253</ArticleId></ArticleIdList></Reference><Reference><Citation>Marchlik E., et al. , Mice lacking Tbk1 activity exhibit immune cell infiltrates in multiple tissues and increased susceptibility to LPS-induced lethality. J. Leukoc Biol. 88, 1171&#x2013;1180 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20651301</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito Y., et al. , RIPK1 mediates axonal degeneration by promoting inflammation and necroptosis in ALS. Science 1979, 603&#x2013;608 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5444917</ArticleId><ArticleId IdType="pubmed">27493188</ArticleId></ArticleIdList></Reference><Reference><Citation>Ajami B., Bennett J. L., Krieger C., Tetzlaff W., Rossi F. M. V., Local self-renewal can sustain CNS microglia maintenance and function throughout adult life. Nat. Neurosci. 10, 1538&#x2013;1543 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">18026097</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;nez-Muriana A., et al. , CSF1R blockade slows the progression of amyotrophic lateral sclerosis by reducing microgliosis and invasion of macrophages into peripheral nerves. Sci. Rep. 6, 1&#x2013;13 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4865981</ArticleId><ArticleId IdType="pubmed">27174644</ArticleId></ArticleIdList></Reference><Reference><Citation>Ajami B., et al. , Single-cell mass cytometry reveals distinct populations of brain myeloid cells in mouse neuroinflammation and neurodegeneration models. Nat. Neurosci. 21, 541&#x2013;551 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8629134</ArticleId><ArticleId IdType="pubmed">29507414</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Erchia A. M., et al. , Massive transcriptome sequencing of human spinal cord tissues provides new insights into motor neuron degeneration in ALS. Sci. Rep. 7, 10046 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5577269</ArticleId><ArticleId IdType="pubmed">28855684</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H., et al. , A Unique Microglia Type Associated with Restricting Development of Alzheimer&#x2019;s Disease. Cell, 169, 1276&#x2013;1290 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., Colonna M., Microglia in Alzheimer&#x2019;s disease at single-cell level. Are there common patterns in humans and mice? J. Exp. Med. 218, e20202717 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8302448</ArticleId><ArticleId IdType="pubmed">34292312</ArticleId></ArticleIdList></Reference><Reference><Citation>Yednock T. A., et al. , Prevention of experimental autoimmune encephalomyelitis by antibodies against &#x3b1;4&#x3b2;1 integrin. Nature 356, 63&#x2013;66 (1992).</Citation><ArticleIdList><ArticleId IdType="pubmed">1538783</ArticleId></ArticleIdList></Reference><Reference><Citation>Garofalo S., et al. , Blocking immune cell infiltration of the central nervous system to tame Neuroinflammation in Amyotrophic lateral sclerosis. Brain Behav. Immun. 105, 1&#x2013;14 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35688338</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinman L., Blocking adhesion molecules as therapy for multiple sclerosis: Natalizumab. Nat. Rev. Drug Discovery 4, 510&#x2013;518 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15931259</ArticleId></ArticleIdList></Reference><Reference><Citation>Vercelli A., et al. , Human mesenchymal stem cell transplantation extends survival, improves motor performance and decreases neuroinflammation in mouse model of amyotrophic lateral sclerosis. Neurobiol. Dis. 31, 395&#x2013;405 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18586098</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J., et al. , TDP-43 pathology and neuronal loss in amyotrophic lateral sclerosis spinal cord. Acta Neuropathol. 128, 423&#x2013;437 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4384652</ArticleId><ArticleId IdType="pubmed">24916269</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbeito A. G., Mesci P., Boill&#xe9;e S., Motor neuron-immune interactions: The vicious circle of ALS. J. Neural. Transm (Vienna) 117, 981&#x2013;1000 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3511247</ArticleId><ArticleId IdType="pubmed">20552235</ArticleId></ArticleIdList></Reference><Reference><Citation>Reichert F., Levitzky R., Rotshenker S., Interleukin 6 in intact and injured mouse peripheral nerves. Eur. J. Neurosci. 8, 530&#x2013;535 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">8963444</ArticleId></ArticleIdList></Reference><Reference><Citation>Tofaris G. K., Patterson P. H., Jessen K. R., Mirsky R., Denervated Schwann cells attract macrophages by secretion of leukemia inhibitory factor (LIF) and monocyte chemoattractant protein-1 in a process regulated by interleukin-6 and LIF. J. Neurosci. 22, 6696&#x2013;6703 (2002).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758146</ArticleId><ArticleId IdType="pubmed">12151548</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye Z., Wei J., Zhan C., Hou J., Role of transforming growth factor beta in peripheral nerve regeneration: Cellular and molecular mechanisms. Front Neurosci. 16, 917587 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9234557</ArticleId><ArticleId IdType="pubmed">35769702</ArticleId></ArticleIdList></Reference><Reference><Citation>Berriat F., Lobsiger C. S., Boill&#xe9;e S., The contribution of the peripheral immune system to neurodegeneration. Nat Neurosci. 26, 942&#x2013;954 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37231108</ArticleId></ArticleIdList></Reference><Reference><Citation>Cugurra A., et al. , Skull and vertebral bone marrow are myeloid cell reservoirs for the meninges and CNS parenchyma. Science 373, eabf7844 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8863069</ArticleId><ArticleId IdType="pubmed">34083447</ArticleId></ArticleIdList></Reference><Reference><Citation>Mezu-Ndubuisi O. J., Maheshwari A., The role of integrins in inflammation and angiogenesis. Pediatr. Res. 89, 1619&#x2013;1626 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8249239</ArticleId><ArticleId IdType="pubmed">33027803</ArticleId></ArticleIdList></Reference><Reference><Citation>Rakhit R., et al. , An immunological epitope selective for pathological monomer-misfolded SOD1 in ALS. Nat. Med. 13, 754&#x2013;759 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17486090</ArticleId></ArticleIdList></Reference><Reference><Citation>Bieniek K. F., et al. , Tau pathology in frontotemporal lobar degeneration with C9ORF72 hexanucleotide repeat expansion. Acta Neuropathol. 125, 289&#x2013;302 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3551994</ArticleId><ArticleId IdType="pubmed">23053135</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>